Citadel Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-500
| Closed | -$925 | – | 15719 |
|
|
2023
Q1 | $925 | Buy |
500
+400
| +400% | +$495 | ﹤0.01% | 14397 |
|
|
2022
Q4 | $111 | Buy |
+100
| New | +$142 | ﹤0.01% | 14757 |
|
|
2022
Q2 | – | Sell |
-16,200
| Closed | -$110K | – | 14608 |
|
|
2022
Q1 | $110K | Buy |
+16,200
| New | +$115K | ﹤0.01% | 12189 |
|
|
2021
Q3 | – | Sell |
-149,000
| Closed | -$1.01M | – | 14985 |
|
|
2021
Q2 | $1.01M | Sell |
149,000
-97,700
| -40% | -$812K | ﹤0.01% | 8339 |
|
|
2021
Q1 | $2.53M | Buy |
246,700
+115,400
| +88% | +$1.26M | ﹤0.01% | 5840 |
|
|
2020
Q4 | $919K | Buy |
131,300
+87,600
| +200% | +$682K | ﹤0.01% | 6976 |
|
|
2020
Q3 | $357K | Buy |
43,700
+28,700
| +191% | +$178K | ﹤0.01% | 7853 |
|
|
2020
Q2 | $104K | Sell |
15,000
-8,000
| -35% | -$43.2K | ﹤0.01% | 8973 |
|
|
2020
Q1 | $109K | Sell |
23,000
-11,200
| -33% | -$64.5K | ﹤0.01% | 8578 |
|
|
2019
Q4 | $299K | Buy |
+34,200
| New | +$185K | ﹤0.01% | 7590 |
|
|
2018
Q4 | – | Sell |
-20,500
| Closed | -$133K | – | 9964 |
|
|
2018
Q3 | $133K | Sell |
20,500
-16,900
| -45% | -$126K | ﹤0.01% | 8453 |
|
|
2018
Q2 | $286K | Buy |
+37,400
| New | +$539K | ﹤0.01% | 7297 |
|
Other funds holding JNCE
Citadel Advisors's JNCE Position: Q2 2023 in Review
Citadel Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 77,599 shares — an estimated $144K sold.
Citadel Advisors first reported a position in JNCE in Q2 2017 and held it in 22 quarters. The position peaked at $20.1M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Citadel Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 77,599 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $144K.
- Citadel Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 22 quarters.
- Citadel Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $20.1M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.